Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

NCT01612039 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: ASP3291
DRUG: Placebo

Sponsor

Telsar Pharma Inc.